Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3SLC6A2
The experimentally established mechanism targets of Racephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.81 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.81 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.47 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.81 |
| ▸ | RGS12 | O14924 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pseudoephedrine SCHEMBL41308 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4EKMT2ANPSR1 | |
| Racephedrine SCHEMBL10995708 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4EKMT2ANPSR1 | |
| Ephedrine SCHEMBL41262 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4EKMT2ANPSR1 | |
| Ephedrine SCHEMBL547932 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4EKMT2ANPSR1 | |
| Racephedrine SCHEMBL41263 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4EKMT2ANPSR1 | |
| Pseudoephedrine SCHEMBL41309 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAKDM4EKMT2ANPSR1 | |
| Pseudoephedrine SCHEMBL6229122 | 0.98 | ALDH1A1 (0.96) | ALDH1A1LMNAKDM4EKMT2ANPSR1 | |
| Racephedrine SCHEMBL6229123 | 0.98 | ALDH1A1 (0.96) | ALDH1A1LMNAKDM4EKMT2ANPSR1 | |
| Racephedrine SCHEMBL28900784 | 0.98 | ALDH1A1 (0.96) | ALDH1A1LMNAKDM4EKMT2ANPSR1 | |
| Ephedrine SCHEMBL4785 | 0.90 | CYP2D6 (1.00) | ALDH1A1LMNAKDM4EKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170052-A1 | EPHEDRINE LIQUID FORMULATIONS | FRESENIUS KABI AUSTRIA GMBH (AT) | 2025-05-29 | — | — | US | claimed |
| US-20250143905-A1 | TOPICAL TREATMENT FOR ANORECTAL DISORDERS WITH AND WITHOUT SEAT CUSHION | CUTLER ROBERT S (US) | 2025-05-08 | — | — | US | claimed |
| EP-4440559-A1 | EPHEDRINE LIQUID FORMULATIONS | Fresenius Kabi Austria GmbH (AT) | 2024-10-09 | — | — | EP | claimed |
| US-20240307323-A1 | EPHEDRINE COMPOSITIONS AND METHODS | NEVAKAR INJECTABLES INC (US) | 2024-09-19 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-12029710-B2 | Ephedrine compositions and methods | NEVAKAR INJECTABLES INC. (US) | 2024-07-09 | — | — | US | claimed |
| US-20240091139-A1 | EPHEDRINE LIQUID FORMULATIONS | FRESENIUS KABI AUSTRIA GMBH (AT) | 2024-03-21 | — | — | US | claimed |
| US-20240041773-A1 | POWDER MIXING DEVICE, AND USES THEREOF | UNIV CONNECTICUT (US) | 2024-02-08 | — | — | US | claimed |
| US-20230172840-A1 | EPHEDRINE LIQUID FORMULATIONS | FRESENIUS KABI AUSTRIA GMBH (AT) | 2023-06-08 | — | — | US | claimed |
| WO-2023100031-A1 | EPHEDRINE LIQUID FORMULATIONS | FRESENIUS KABI AUSTRIA GMBH (AT) | 2023-06-08 | — | — | WO | claimed |
| US-5720962-A | Analgesic lotion for hemorrhoids and method of making such lotion | AU PHARMACEUTICALS, INC. (US) | 1998-02-24 | — | — | US | claimed |
| CN-1171045-A | Compositions for treating hemorrhoids and methods of use thereof | WHITEHALL LAB LTD (GB) | 1998-01-21 | — | — | CN | claimed |
| WO-1996040054-A2 | INTRAURETHRAL PHARMACOTHERAPY OF INCONTINENCE | IOTEK, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1994018970-A1 | COLD/SINUS PREPARATION CONSISTING OF PHENINDAMINE TARTARATE WITH OR WITHOUT THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | claimed |
| EP-0241615-B1 | A PHARMACEUTICAL COMPOSITION OF PHENINDAMINE HAVING ENHANCED RELEASE CHARACTERISTICS | WARNER-LAMBERT COMPANY (US) | 1991-09-18 | — | — | EP | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| US-4877781-A | TIXOCORTOL PIVALATE, EPHEDRINE SULFATE, PRAMOXINE HYDROCHLORIDE; ANTIINFLAMMATORY AGENTS FOR HEMORRHOIDS | LaHaye, Peter G. (US) | 1989-10-31 | — | — | US | claimed |
| EP-0241615-A1 | A pharmaceutical composition of phenindamine having enhanced release characteristics | WARNER-LAMBERT COMPANY (US) | 1987-10-21 | — | — | EP | claimed |
| US-4235236-A | Device for dispensing drug by combined diffusional and osmotic operations | ALZA CORPORATION (US) | 1980-11-25 | — | — | US | claimed |
| US-RE29875-E | THEOPHYLLINE SOLUBILIZED BY GLYCERYL GUAIACOLATE, POTASSIUM GUAIACOL SULFONATE OR GUAIACOL | MEAD JOHNSON & COMPANY (US) | 1979-01-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307323-A1 | EPHEDRINE COMPOSITIONS AND METHODS | EPHB1, EPHA1, EPHB6 | ADRA2C 74/4885ADRA1A 109/4885ADRA2A 229/4885 |
| US-20230172840-A1 | EPHEDRINE LIQUID FORMULATIONS | EPHA5, EFNA1, EPHA1 | ADRA2C 321/4885ADRA1A 497/4885ADRA2A 939/4885 |
| US-20240091139-A1 | EPHEDRINE LIQUID FORMULATIONS | EPHA5, EFNA1, EPHA1 | ADRA2C 321/4885ADRA1A 497/4885ADRA2A 939/4885 |
| US-12029710-B2 | Ephedrine compositions and methods | EPHB1, EPHA1, EPHB6 | ADRA2C 74/4885ADRA1A 109/4885ADRA2A 229/4885 |
| US-20250170052-A1 | EPHEDRINE LIQUID FORMULATIONS | EPHA5, EFNA1, EPHA1 | ADRA2C 321/4885ADRA1A 497/4885ADRA2A 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.